Diagnostic BioSystems, México Office

28/11/2024

Happy Thanksgiving!!!

31/12/2023

Happy New Year 2024😃

22/12/2023

27/11/2023

27/11/2023

27/11/2023

30/08/2023

Diagnostic Biosystems organized a brief Demonstration Workshop on IHC in association with League Against Cancer Hospital, Honduras.
Website: https://dbiosys.com
Photos: https://dbiosys.com/trainings-workshops

30/08/2023

CD5 antigen is usually expressed on the surface of practically all mature peripheral human T cells, but only weakly expressed in immature T cells. Therefore, CD5 is detected by IHC in most T cell lymphomas and leukemias, including 75% of peripheral T cell lymphoma and 85% of T lymphoblastic lymphoma/leukemia. CD5 is also expressed in subset of normal human B cells. CD20+ small B cell lymphomas can be identified and subclassified by CD5 expression. Small lymphocytic lymphoma/leukemia and mantle cell lymphoma are CD5 positive, whereas follicular lymphoma, marginal zone lymphoma and lymphoplasmacytic lymphoma are CD5 negative. CD5 IHC can be very useful in the identification of thymic carcinoma from thymoma since CD5 is expressed on the surface of thymic carcinoma cells.

CD5: https://bit.ly/DBS-CD5
Website: www.dbiosys.com
Order Now: https://bit.ly/dbs-distributors

05/02/2023

World Cancer Day!


As a Cancer diagnostic’s company, Diagnostics BioSystems joins the global uniting initiative with the aim to raise awareness and education about the most dreaded disease “Cancer”.

February 4th is celebrated as the “World Cancer Day” an initiative to educate people about cancer and pressing individuals across the globe to take early action against the disease.

Breast, lung, prostate, and colorectal cancers account for almost 50% of cancer cases which can be prevented by avoiding the risk factors associated with the specific cancer types. These cancers can be treated at an early stage provided they are detected early. Hence with the concept of raising awareness, early detection and screening programs are key strategies that should be implemented.

Rationalizing the theme for World cancer day 2023 “Close the Care Gap”, Diagnostic BioSystems is continuously developing and have already developed over thousands of products for cancer diagnostics.

We believe that every single contribution makes a difference and together we can reduce the global impact of Cancer.

Website: https://dbiosys.com

24/12/2022

Feliz Navidad y Próspero Año Nuevo!!!
🍁 🎉 🎄 🎁

15/12/2022

SATB2 (EP 281) - Anticuerpo Monoclonal de Conejo,
Nº de Catálogo: RMAB112, RMPD112

La Proteína especial de unión a secuencias ricas en AT 2 (SATB2) es un marcador descrito recientemente que funciona como un factor de transcripción asociado a la matriz nuclear. Se ha informado de que SATB2, en combinación con CK20, podría identificar casi todos los carcinomas colorrectales, incluidos los carcinomas colorrectales poco diferenciados. Los carcinomas gastrointestinales (GI) superiores y los carcinomas ductales pancreáticos suelen ser negativos para SATB2, y los carcinomas ováricos, los adenocarcinomas pulmonares y los adenocarcinomas de otro origen rara vez son positivos para SATB2. Por lo tanto, SATB2 es un buen marcador para identificar un carcinoma de origen colorrectal cuando se trabaja con un tumor de primario desconocido. Puede ayudar a diferenciar una metástasis colorrectal (SATB2+) de un adenocarcinoma pulmonar primario mucinoso.
Más información: https://bit.ly/SATB2
Distribuidores: https://bit.ly/DBS-Distributors

SATB2 (EP 281) - Rabbit Monoclonal Antibody,
Catalog No: RMAB112, RMPD112


Special AT-rich sequence-binding protein 2 (SATB2) is a recently described marker that functions as a nuclear matrix-associated transcription factor. It has been reported that SATB2, in combination with CK20, could identify almost all colorectal carcinomas, including poorly differentiated colorectal carcinomas. Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2, and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive for SATB2. Therefore, SATB2 is a good marker for identifying a carcinoma of colorectal origin when working on a tumor of unknown primary. It can help differentiate colorectal metastasis (SATB2+) from primary pulmonary adenocarcinoma of mucinous.

Read More: https://bit.ly/SATB2
Distributors: https://bit.ly/DBS-Distributors